Double blind randomised controlled trial (RCT) on the utility of personalised bronchiectasis action management plans (BAMP) for children with bronchiectasis

Bronchiectasis is a chronic disease of the airways, and remains one of the most neglected diseases in respiratory health globally. Bronchiectasis is characterised by abnormal dilatation of the bronchi caused by protracted inflammation, and by chronic productive or wet cough. Current evidence based guidelines seek to improve symptom control, reduce frequency of exacerbations and preserve lung function. Strategies include through regular physiotherapy and airway clearance manoeuvres, regular exercise, optimal nutrition, reducing environmental risk factors (including tobacco smoke) and keeping recommended vaccines are up to date. In children with asthma, personalised asthma action plans are recommended in all settings, as there is robust evidence that their use improve clinical outcomes. Similar personalised bronchiectasis action management plans (BAMP) for children with bronchiectasis have not yet been evaluated.

Aim:

• To determine if the routine use of a personalised written BAMP (compared to standard care) reduces non-scheduled doctor visits.
• Determine if the routine use of a personalised BAMP:
  • reduces the rate of exacerbation over the intervention period
  • improves cough-specific quality of life (PC-QoL18)
  • improves the early uptake of yearly influenza vaccine (by 30th May each year)